MEDP Stock Recent News
MEDP LATEST HEADLINES
The Zacks Medical - Services industry is growing on digital healthcare adoption. MEDP, HQY and AMEH are set to gain the most.
Medpace (MEDP) possesses solid growth attributes, which could help it handily outperform the market.
Medpace is one the largest Clinical Research Organisations in the market, and consistently winning market share. On April 24, Medpace presented its earnings for the first quarter of FY23, showing operative strength in a challenging market environment.
We've got a look at this company, what's going on with Pepsi, and other market news.
Medpace (MEDP) is well positioned to outperform the market, as it exhibits above-average growth in financials.
You might be familiar with some of the brands, but the company's name is probably not on your radar.
Medpace (MEDP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Medpace (MEDP) came out with quarterly earnings of $2.27 per share, beating the Zacks Consensus Estimate of $1.76 per share. This compares to earnings of $1.69 per share a year ago.
Medpace easily beat Wall Street's first-quarter projections late Monday and boosted its full-year outlook. In response, MEDP stock rocketed.
Strong financial growth in 2022, with healthy key performance metrics. Risks are contract cancellations, drug development unpredictability, and industry consolidation.